Tecvayli (teclistamab)

Numéro de dossier de l’AMC: 22654

État des négociations:

Négociation envisagée

Indication(s):

Teclistamab injection is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Promoteur/fabricant:

Janssen Inc.

Numéro de projet de l’AMC:

PC0332-000

Lettre-contrat de l’APP:

Sans objet

Conclusion du processus de négociation:

Sans objet